BioNTech (BNTX) CEO Sahin Ugur Sells 64,000 Shares

What Happened
Sahin Ugur, CEO of BioNTech (BNTX), sold a total of 64,000 ordinary shares in two open-market transactions. On 2026-09-17 he sold 34,000 shares at $98.60 for $3,352,342, and on 2026-09-18 he sold 30,000 shares at $96.22 for $2,886,729. These were sales (not purchases or option exercises) and thus are typically considered routine liquidity rather than a direct bullish signal.

Key Details

• Transaction dates & prices:
  • 2026-09-17: 34,000 shares @ $98.60 = $3,352,342
  • 2026-09-18: 30,000 shares @ $96.22 = $2,886,729
• Total disposed: 64,000 shares for ~$6,239,071.
• Shares owned after transaction: Not specified in the provided excerpt. The Form 4 should be consulted for the exact post-transaction beneficial ownership figure.
• Footnotes: Shares are held by Medine GmbH, of which the reporting person is sole shareholder. 106,721 shares noted are held in trust for an individual; Medine GmbH exercises voting power (but not dispositive power) over those trust shares. The reporting person may be deemed to beneficially own the shares held by Medine GmbH.
• Trading plan: Sales were effected under a Rule 10b5-1 trading plan established June 3, 2026.
• Timeliness: Form 4 was filed on 2026-09-18 covering transactions on 2026-09-17 and 2026-09-18; this appears to be filed within the standard two-business-day window (i.e., timely).

Context: These were pre-arranged 10b5-1 plan sales, which allow insiders to sell shares according to a set schedule and reduce the implication that trades reflect contemporaneous private information. Sales are generally less informative than purchases about an insider’s view of the company’s prospects.